Molecular mechanisms of VEGF-A action during tissue repair

被引:98
作者
Eming, Sabine A. [1 ]
Krieg, Thomas [1 ]
机构
[1] Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany
关键词
D O I
10.1038/sj.jidsymp.5650016
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Vascular endothelial growth factor-A (VEGF-A) is a crucial mediator of vascular hyperpermeability, angiogenesis, and inflammation, processes intimately involved in tissue repair. Although much emphasis has been placed on understanding the synthesis and stability of VEGF-A mRNA, relatively little attention has been given to the study of the stability and processing of VEGF-A proteins themselves. In recent years, several studies indicated that VEGF-A protein activity is highly controlled through interaction with angiogenic or non-angiogenic mediators. We analyzed mechanisms that might control extracellular VEGF-A processing during wound repair. First, our studies provide evidence that VEGF-A protein is a target of proteases present in the microenvironment of human chronic non-healing wounds. Serine proteases, in particular plasmin cleave VEGF165 and digested VEGF fragments, showed decreased mitogenic activity. Inactivation of the plasmin cleavage site Arg110/Ala111 preserved the structural integrity and increased the angiogenic potency of VEGF165 when tested in an impaired healing mouse model. Secondly, we identified significantly increased levels of the potent VEGF-A inhibitor, the soluble form of the VEGF receptor VEGFR-1 (sVEGFR-1) in non-healing wounds when compared to healing wounds. Wound closure in healing and non-healing wounds correlated significantly with a decline in sVEGFR-1 levels. These observations support the concept that VEGF-A and VEGF-A receptors are important mediators in tissue repair. Further, our data provide mechanisms how VEGF-A-mediated interactions are disturbed during impaired healing.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 59 条
[1]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].
ALON, T ;
HEMO, I ;
ITIN, A ;
PEER, J ;
STONE, J ;
KESHET, E .
NATURE MEDICINE, 1995, 1 (10) :1024-1028
[3]   Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders [J].
Autiero, M ;
Luttun, A ;
Tjwa, M ;
Carmeliet, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1356-1370
[4]   Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1 [J].
Banks, RE ;
Forbes, MA ;
Searles, J ;
Pappin, D ;
Canas, B ;
Rahman, D ;
Kaufmann, S ;
Walters, CE ;
Jackson, A ;
Eves, P ;
Linton, G ;
Keen, J ;
Walker, JJ ;
Selby, PJ .
MOLECULAR HUMAN REPRODUCTION, 1998, 4 (04) :377-386
[5]  
Barleon B, 1997, CANCER RES, V57, P5421
[6]   Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors [J].
Barleon B. ;
Reusch P. ;
Totzke F. ;
Herzog C. ;
Keck C. ;
Martiny-Baron G. ;
Marmé D. .
Angiogenesis, 2001, 4 (2) :143-154
[7]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[8]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) BY EPIDERMAL-KERATINOCYTES DURING WOUND-HEALING [J].
BROWN, LF ;
YEO, KT ;
BERSE, B ;
YEO, TK ;
SENGER, DR ;
DVORAK, HF ;
VANDEWATER, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1375-1379
[9]   Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 [J].
Carmeliet, P ;
Ng, YS ;
Nuyens, D ;
Theilmeier, G ;
Brusselmans, K ;
Cornelissen, I ;
Ehler, E ;
Kakkar, VV ;
Stalmans, I ;
Mattot, V ;
Perriard, JC ;
Dewerchin, M ;
Flameng, W ;
Nagy, A ;
Lupu, F ;
Moons, L ;
Collen, D ;
D'Amore, PA ;
Shima, DT .
NATURE MEDICINE, 1999, 5 (05) :495-502
[10]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583